DENVER, Sept. 15 /PRNewswire-FirstCall/ -- Osmotics Corporation, a specialty pharmaceutical company focused on dermatology and antibiotics, today announced that Peter Elias, MD, Professor of Dermatology at University of California, San Francisco, has joined the Company as Chief Scientific Officer. Dr. Elias has served on the Scientific Advisory Board of Osmotics since 2000 as Chairman of the Scientific Advisory Board.
"Dr. Elias brings an outstanding record of accomplishments in basic research on skin as well as the development of clinical research programs in the dermatological arena and we are extremely fortunate to have Dr. Elias join us as our Chief Scientific Officer," commented Steven Porter, Chief Executive Officer of Osmotics Corporation. "Given the depth of Dr. Elias' experience, his appointment is critical to us as we transition from a cosmeceutical company to a specialty pharmaceutical company. His knowledge and expertise has been invaluable to Osmotics during his time on the Scientific Advisory Board and we look forward to working even more closely with him under this expanded relationship."
"Dr. Elias' research is the basis for one of our core technology platforms for skin barrier repair, which has broad application potential in the prevention and treatment of a wide variety of skin disorders including neonatal skin care and atopic dermatitis," stated Carl Genberg, President of Osmotics Pharma, a division of Osmotics Corporation. "For more than 30 years, his research on the epidermal barrier has been considered by many to have provided some of the most ground breaking advances in understanding how the epidermal layers are formed and functions including its role in maintaining internal water balance and its defense against foreign elements both outside and inside."
Dr. Elias is a Professor of Dermatology at University of California, San Francisco and a staff physician at the Veterans Administration Hospital. Well-known throughout the dermatology field, Dr. Elias has authored over 300 peer reviewed journal articles in the field of dermatology, as well as over 100 review articles and book chapters. In addition, he is on the editorial board of several journals of clinical and investigative dermatology. Dr. Elias is also an elected member of the American Society of Clinical Investigation and American Association of Professors.
Dr. Elias established the classic "bricks and mortar" model of the stratum corneum (outer layer of the skin) more than 30 years ago. Elias' detailed molecular dissection of the "bricks and mortar" model has provided insights into the basis of dry, scaly skin disorders that range from the cosmetic problems of winter xerosis to severe conditions such as psoriasis.
Dr. Elias has received numerous awards of recognition for his work including the Society for Investigative Dermatology's Montagna Award for excellence in scientific research in dermatology; the Literature and Maison G. de Navarre Awards, Society for Cosmetic Chemists; and the Robert Chesebrough Award for Research.
Osmotics is a specialty pharmaceutical company focused on the discovery, development and commercialization of a portfolio of innovative therapeutic and cosmeceutical skin care products as well as novel antibiotics. Osmotics works with leading university medical centers and renowned scientists around the world to utilize the latest breakthroughs and most advanced thinking in developing truly effective products. Founded in 1992 by Steven and Francine Porter, Osmotics currently markets more than 32 cosmeceutical products in its skin care line nationally through Saks Fifth Avenue, Nordstrom, Sephora and leading dermatologists.
CONTACT: Evan Smith, CFA, +1-212-896-1251, or Erica Pettit,+1-212-896-1248, both of KCSA Worldwide, for Osmotics Corporation